中国临床康复
中國臨床康複
중국림상강복
CHINESE JOURNAL OF CLINICAL REHABILITATION
2005年
29期
168-169
,共2页
硬皮病%系统性%抗体%抗核%免疫学试验
硬皮病%繫統性%抗體%抗覈%免疫學試驗
경피병%계통성%항체%항핵%면역학시험
背景:抗核抗体、抗着丝点抗体、抗细胞浆抗体、抗拓扑异构酶I抗体是系统性硬皮病疾病形成中产生的几种主要的自身抗体,并与疾病的发展有着密切的关系.目的:通过对系统性硬皮病患者各种自身抗体和蛋白的检测,探讨其在预后评估中的价值.设计:病例-对照实验.单位:江西医学院第二附属医院检验科.对象:选择1995-12/2004-12江西医学院第二附属医院门诊或住院系统性硬皮病患者74例,男19例,女55例,年龄12～59岁,包括皮肤弥漫型系统性硬皮病46例、皮肤局限型系统性硬皮病24例及重叠综合征4例.对照组为同期住院其他疾病患者40例,男14例,女26例,年龄19～54岁.方法:采用间接免疫荧光法检测抗核抗体、抗着丝点抗体、抗细胞浆抗体.采用免疫印迹法检测抗拓扑异构酶I抗体.采用速率散射比浊法检测血清中免疫球蛋白、C-反应蛋白及类风湿因子水平.主要观察指标:①两组患者抗核抗体、抗着丝点抗体、抗拓扑异构酶I抗体、抗细胞浆抗体检测结果.②两组患者血清中免疫球蛋白、C-反应蛋白及类风湿因子水平.结果:74例系统性硬皮病患者,对照组40例的血样合格,全部进入结果分析.①抗核抗体、抗着丝点抗体、抗拓扑异构酶I抗体、抗细胞浆抗体阳性率:系统性硬皮病患者明显高于对照组[66%(49/74),53%(39/74),39%(29/74),7%(5/74),0,(x2=57.15,P＜0.01)].皮肤弥漫型系统性硬皮病患者抗核抗体阳性率明显低于皮肤局限型系统性硬皮病患者[57%(26/46),83%(20/24),(x2=5.03,P＜0.05)]、抗拓扑异构酶I抗体阳性率明显高于皮肤局限型系统性硬皮病患者[48%(22/46),21%(5/24),(x2=4.85,P＜0.05)].③系统性硬皮病患者免疫球蛋白G和类风湿因子水平明显高于对照组[(16.89±11.94),(11.89±2.05)g/L;(23.06±6.18),(22.44±5.53)IU/mL,(t=8.01,2.46,P＜0.01)].结论:系统性硬皮病患者血清抗核抗体、抗着丝点抗体、抗细胞浆抗体和抗拓扑异构酶I抗体阳性率及免疫球蛋白G和类风湿因子水平明显增高,以上实验室指标的检测对预后评估有重要意义.
揹景:抗覈抗體、抗著絲點抗體、抗細胞漿抗體、抗拓撲異構酶I抗體是繫統性硬皮病疾病形成中產生的幾種主要的自身抗體,併與疾病的髮展有著密切的關繫.目的:通過對繫統性硬皮病患者各種自身抗體和蛋白的檢測,探討其在預後評估中的價值.設計:病例-對照實驗.單位:江西醫學院第二附屬醫院檢驗科.對象:選擇1995-12/2004-12江西醫學院第二附屬醫院門診或住院繫統性硬皮病患者74例,男19例,女55例,年齡12～59歲,包括皮膚瀰漫型繫統性硬皮病46例、皮膚跼限型繫統性硬皮病24例及重疊綜閤徵4例.對照組為同期住院其他疾病患者40例,男14例,女26例,年齡19～54歲.方法:採用間接免疫熒光法檢測抗覈抗體、抗著絲點抗體、抗細胞漿抗體.採用免疫印跡法檢測抗拓撲異構酶I抗體.採用速率散射比濁法檢測血清中免疫毬蛋白、C-反應蛋白及類風濕因子水平.主要觀察指標:①兩組患者抗覈抗體、抗著絲點抗體、抗拓撲異構酶I抗體、抗細胞漿抗體檢測結果.②兩組患者血清中免疫毬蛋白、C-反應蛋白及類風濕因子水平.結果:74例繫統性硬皮病患者,對照組40例的血樣閤格,全部進入結果分析.①抗覈抗體、抗著絲點抗體、抗拓撲異構酶I抗體、抗細胞漿抗體暘性率:繫統性硬皮病患者明顯高于對照組[66%(49/74),53%(39/74),39%(29/74),7%(5/74),0,(x2=57.15,P＜0.01)].皮膚瀰漫型繫統性硬皮病患者抗覈抗體暘性率明顯低于皮膚跼限型繫統性硬皮病患者[57%(26/46),83%(20/24),(x2=5.03,P＜0.05)]、抗拓撲異構酶I抗體暘性率明顯高于皮膚跼限型繫統性硬皮病患者[48%(22/46),21%(5/24),(x2=4.85,P＜0.05)].③繫統性硬皮病患者免疫毬蛋白G和類風濕因子水平明顯高于對照組[(16.89±11.94),(11.89±2.05)g/L;(23.06±6.18),(22.44±5.53)IU/mL,(t=8.01,2.46,P＜0.01)].結論:繫統性硬皮病患者血清抗覈抗體、抗著絲點抗體、抗細胞漿抗體和抗拓撲異構酶I抗體暘性率及免疫毬蛋白G和類風濕因子水平明顯增高,以上實驗室指標的檢測對預後評估有重要意義.
배경:항핵항체、항착사점항체、항세포장항체、항탁복이구매I항체시계통성경피병질병형성중산생적궤충주요적자신항체,병여질병적발전유착밀절적관계.목적:통과대계통성경피병환자각충자신항체화단백적검측,탐토기재예후평고중적개치.설계:병례-대조실험.단위:강서의학원제이부속의원검험과.대상:선택1995-12/2004-12강서의학원제이부속의원문진혹주원계통성경피병환자74례,남19례,녀55례,년령12～59세,포괄피부미만형계통성경피병46례、피부국한형계통성경피병24례급중첩종합정4례.대조조위동기주원기타질병환자40례,남14례,녀26례,년령19～54세.방법:채용간접면역형광법검측항핵항체、항착사점항체、항세포장항체.채용면역인적법검측항탁복이구매I항체.채용속솔산사비탁법검측혈청중면역구단백、C-반응단백급류풍습인자수평.주요관찰지표:①량조환자항핵항체、항착사점항체、항탁복이구매I항체、항세포장항체검측결과.②량조환자혈청중면역구단백、C-반응단백급류풍습인자수평.결과:74례계통성경피병환자,대조조40례적혈양합격,전부진입결과분석.①항핵항체、항착사점항체、항탁복이구매I항체、항세포장항체양성솔:계통성경피병환자명현고우대조조[66%(49/74),53%(39/74),39%(29/74),7%(5/74),0,(x2=57.15,P＜0.01)].피부미만형계통성경피병환자항핵항체양성솔명현저우피부국한형계통성경피병환자[57%(26/46),83%(20/24),(x2=5.03,P＜0.05)]、항탁복이구매I항체양성솔명현고우피부국한형계통성경피병환자[48%(22/46),21%(5/24),(x2=4.85,P＜0.05)].③계통성경피병환자면역구단백G화류풍습인자수평명현고우대조조[(16.89±11.94),(11.89±2.05)g/L;(23.06±6.18),(22.44±5.53)IU/mL,(t=8.01,2.46,P＜0.01)].결론:계통성경피병환자혈청항핵항체、항착사점항체、항세포장항체화항탁복이구매I항체양성솔급면역구단백G화류풍습인자수평명현증고,이상실험실지표적검측대예후평고유중요의의.
BACKGROUND: Antinuclear antibody, anticentromere antibody, anti-cytoplasm antibody, and antibody against SCL-70 are the main self-antibodies involved in systemic scleroderma (SSc) and are closely connected with the development of SSc.OBJECTIVE: To probe the value of various self-antibodies and proteins in evaluating the functional prognosis of patients with SSc. DESIGN: Case-control study.SETTING: Clinical Laboratory of Second Hospital Affiliated to Jiangxi Medical College.PARTICIPANTS: Totally 74 patients, 19 males and 55 females aged 12-59years old, were confirmed of SSc at the outpatient and inpatient departments of Second Hospital Affiliated to Jiangxi Medical College between December 1995 and December 2004. There were 46 cases of diffuse cutaneous SSc, 24 cases of localized cutaneous SSc, and 4 cases of overlapping syndrome. Meanwhile40 inpatients (14 males and 26 females aged 19-54years old) who received treatment due to other diseases were recruited from the same hospital.METHODS: The level of antinuclear antibody, anticentromere antibody,and anti-cytoplasm antibody was detected with indirect irnmuneofluorescence assay; antibody against SCL-70 was detected with Western blot; the level of serum immunoglobulin, C-reactive protein (CRP) and rheumatoid factor was examined with velocity dispersion turbidimetry.ticentromere antibody, anti-cytoplasm antibody, and antibody against SCL-70;RESULTS: Blood samples collected from the 74 patients with SSc and 40controls were proved eligible and all data entered the final statistical analanti-cytoplasm antibody, and antibody against SCL-70: It was obviously higher in SSc group than in control group [66% (49/74), 53% (39/74), 39%(29/74), 7% (5/74), 0, (x2=57.15, P ＜ 0.01)]. The positive rate of antinuclear antibody in patients with diffuse cutaneous SSc was significantly lower than in patients with localized cutaneous SSc [57% (26/46), 83%(20/24),(x2=5.03, P ＜ 0.05)], but the positive rate of antibody against SCL70 was significantly higher than localized cutaneous SSc [48% (22/46),rheumatoid factor in patients with SSc was markedly higher thanin control group [(16.89±11.94), (11.89±2.05) g/L; (23.06±6.18), (22.44±5.53) IU/mL,t=8.01, 2.46, P ＜ 0.01].CONCLUSION: The positive rate of antinuclear antibody, anticentromere antibody, anti-cytoplasm antibody, and antibody against SCL-70, as well as the level of immunoglobulin G and rheumatoid factor were obviously increased in patients with SSc, suggesting that these experimental parameters have the value in evaluating the prognosis of SSc.
